McCauley; John A.
Patent Applications and Registrations
Patent applications and USPTO patent grants for McCauley; John A..The latest application filed is for "tetracyclic heterocycle compounds useful as hiv integrase inhibitors".
Company Profile
12.49.67
- McCauley; John A. - Maple Glen PA
- MCCAULEY; John A. - West Point PA US
- McCauley; John A. - Rahway NJ
- McCauley, John A - Maple Glen PA
- McCauley; John A. - Philadelphia PA
Patent Activity
| Patent | Date |
|---|---|
| Tetracyclic Heterocycle Compounds Useful As Hiv Integrase Inhibitors App 20220259227 - Hartingh; Timothy John ; et al. | 2022-08-18 |
| Tetracyclic heterocycle compounds useful as HIV integrase inhibitors Grant 11,358,711 - Graham , et al. June 14, 2 | 2022-06-14 |
| Tricyclic Heterocycle Compounds Useful As Hiv Integrase Inhibitors App 20210309671 - YU; Tao ; et al. | 2021-10-07 |
| Tricyclic Heterocycle Compounds Useful As Hiv Integrase Inhibitors App 20210115044 - Yu; Tao ; et al. | 2021-04-22 |
| Tricyclic heterocycle compounds useful as HIV integrase inhibitors Grant 10,934,312 - Graham , et al. March 2, 2 | 2021-03-02 |
| Fused Tricyclic Heterocyclic Compounds As Hiv Integrase Inhibitors App 20210040096 - Yu; Tao ; et al. | 2021-02-11 |
| Tetracyclic Heterocycle Compounds Useful As Hiv Integrase Inhibitors App 20210009262 - Graham; Thomas H. ; et al. | 2021-01-14 |
| Tetracyclic heterocycle compounds useful as HIV integrase inhibitors Grant 10,829,499 - Graham , et al. November 10, 2 | 2020-11-10 |
| Substituted quinolizine derivatives useful as HIV integrase inhibitors Grant 10,786,488 - Yu , et al. September 29, 2 | 2020-09-29 |
| Heterocyclic Compounds As Hiv Protease Inhibitors App 20200261421 - McKittrick; Brian ; et al. | 2020-08-20 |
| Spirocyclic Pyridotriazine Derivatives useful as HIV integrase inhibitors Grant 10,624,912 - Graham , et al. | 2020-04-21 |
| Amido-substituted pyridotriazine derivatives useful as HIV integrase inhibitors Grant 10,548,910 - Graham , et al. Fe | 2020-02-04 |
| Spirocyclic quinolizine derivatives useful as HIV integrase inhibitors Grant 10,544,155 - Zhang , et al. Ja | 2020-01-28 |
| Tricyclic Heterocycle Compounds Useful As Hiv Integrase Inhibitors App 20200017524 - Graham; Thomas H. ; et al. | 2020-01-16 |
| Substituted Quinolizine Derivatives Useful As Hiv Integrase Inhibitors App 20190365727 - Yu; Tao ; et al. | 2019-12-05 |
| Tetracyclic heterocycle compounds useful as HIV integrase inhibitors Grant 10,479,801 - Graham , et al. Nov | 2019-11-19 |
| Fused Tricyclic Heterocyclic Compounds As Hiv Integrase Inhibitors App 20190322666 - Yu; Tao ; et al. | 2019-10-24 |
| Tetracyclic Heterocycle Compounds Useful As Hiv Integrase Inhibitors App 20190315769 - Graham; Thomas H. ; et al. | 2019-10-17 |
| Fused tricyclic heterocyclic compounds useful for treating HIV infection Grant 10,233,193 - Yu , et al. | 2019-03-19 |
| Spirocyclic Quinolizine Derivatives Useful as HIV Integrase Inhibitors App 20190040076 - Zhang; Yonglian ; et al. | 2019-02-07 |
| Piperazine derivatives as HIV protease inhibitors Grant 10,138,255 - Williams , et al. Nov | 2018-11-27 |
| Spirocyclic Pyridotriazine Derivatives Useful As HIV Integrase Inhibitors App 20180325926 - Graham; Thomas H. ; et al. | 2018-11-15 |
| Amido-Substituted Pyridotriazine Derivatives Useful As HIV Integrase Inhibitors App 20180325927 - Graham; Thomas H. ; et al. | 2018-11-15 |
| Phosphate substituted quinolizine derivatives useful as HIV integrase inhibitors Grant 10,081,647 - Yu , et al. September 25, 2 | 2018-09-25 |
| Fused Tricyclic Heterocyclic Compounds Useful For Treating HIV Infection App 20180194774 - Yu; Tao ; et al. | 2018-07-12 |
| HIV protease inhibitors Grant 9,994,587 - McCauley , et al. June 12, 2 | 2018-06-12 |
| Tetracyclic Heterocycle Compounds Useful As Hiv Integrase Inhibitors App 20180155365 - Graham; Thomas H. ; et al. | 2018-06-07 |
| Fused Tricyclic Heterocyclic Compounds As Hiv Integrase Inhibitors App 20180099967 - Yu; Tao ; et al. | 2018-04-12 |
| Phosphate Substituted Quinolizine Derivatives Useful As Hiv Integrase Inhibitors App 20180051043 - Yu; Tao ; et al. | 2018-02-22 |
| Piperazine derivatives as HIV protease inhibitors Grant 9,840,478 - Williams , et al. December 12, 2 | 2017-12-12 |
| HIV protease inhibitors Grant 9,834,526 - McCauley , et al. December 5, 2 | 2017-12-05 |
| HIV protease inhibitors Grant 9,737,545 - McCauley , et al. August 22, 2 | 2017-08-22 |
| HCV NS3 protease inhibitors Grant 9,738,661 - Liverton , et al. August 22, 2 | 2017-08-22 |
| Hiv Protease Inhibitors App 20170217986 - McCauley; John A. ; et al. | 2017-08-03 |
| Compounds inhibiting leucine-rich repeat kinase enzyme activity Grant 9,718,818 - DeMong , et al. August 1, 2 | 2017-08-01 |
| Fused Tricyclic Heterocyclic Compounds As Hiv Integrase Inhibitors App 20170190701 - Yu; Tao ; et al. | 2017-07-06 |
| Piperazine Derivatives As Hiv Protease Inhibitors App 20170073354 - Williams; Peter D. ; et al. | 2017-03-16 |
| Hiv Protease Inhibitors App 20160311786 - McCauley; John A. ; et al. | 2016-10-27 |
| Hiv Protease Inhibitors App 20160296527 - McCauley; John A. ; et al. | 2016-10-13 |
| Compounds inhibiting leucine-rich repeat kinase enzyme activity Grant 9,440,952 - Miller , et al. September 13, 2 | 2016-09-13 |
| Compounds Inhibiting Leucine-rich Repeat Kinase Enzyme Activity App 20160200722 - DeMong; Duane ; et al. | 2016-07-14 |
| Piperazine Derivatives As Hiv Protease Inhibitors App 20160159752 - Williams; Peter D. ; et al. | 2016-06-09 |
| HIV protease inhibitors Grant 9,315,475 - Beaulieu , et al. April 19, 2 | 2016-04-19 |
| Compounds Inhibiting Leucine-rich Repeat Kinase Enzyme Activity App 20160009682 - Miller; Michael ; et al. | 2016-01-14 |
| Leucine-rich repeat kinase enzyme activity Grant 9,233,977 - McCauley , et al. January 12, 2 | 2016-01-12 |
| HCV NS3 Protease Inhibitors App 20150266897 - Liverton; Nigel J. ; et al. | 2015-09-24 |
| Inhibitors of hepatitis C virus replication Grant 9,090,661 - Coburn , et al. July 28, 2 | 2015-07-28 |
| Macrocyclic compounds as antiviral agents Grant 8,927,569 - Harper , et al. January 6, 2 | 2015-01-06 |
| Inhibitors Of Hepatitis C Virus Replication App 20140371138 - Coburn; Craig A. ; et al. | 2014-12-18 |
| Compositions Useful For The Treatment Of Viral Diseases App 20140328799 - Carroll; Steven S. ; et al. | 2014-11-06 |
| Hepatitis C virus NS3 protease inhibitors Grant 8,828,930 - Liverton , et al. September 9, 2 | 2014-09-09 |
| Hiv Protease Inhibitors App 20140200197 - MCCAULEY; JOHN A. ; et al. | 2014-07-17 |
| Compounds Inhibiting Leucine-rich Repeat Kinase Enzyme Activity App 20130338106 - McCauley; John A. ; et al. | 2013-12-19 |
| Therapeutic compounds Grant 8,591,878 - McCauley , et al. November 26, 2 | 2013-11-26 |
| Leucine-rich Repeat Kinase Enzyme Activity App 20130296317 - McCauley; John A. ; et al. | 2013-11-07 |
| Hcv Ns3 Protease Inhibitors App 20130178413 - McCauley; John A. ; et al. | 2013-07-11 |
| HCV NS3 protease inhibitors Grant 8,461,107 - Liverton , et al. June 11, 2 | 2013-06-11 |
| HCV NS3 protease inhibitors Grant 8,377,874 - Liverton , et al. February 19, 2 | 2013-02-19 |
| HCV NS3 protease inhibitors Grant 8,309,540 - Liverton , et al. November 13, 2 | 2012-11-13 |
| HCV NS3 protease inhibitors Grant 8,278,322 - Holloway , et al. October 2, 2 | 2012-10-02 |
| HCV NS3 protease inhibitors Grant 8,216,999 - Holloway , et al. July 10, 2 | 2012-07-10 |
| Hepatitis C Virus Ns3 Protease Inhibitors App 20120121624 - Liverton; Nigel J. ; et al. | 2012-05-17 |
| Inhibitors Of Hepatitis C Virus Replication App 20120083483 - Coburn; Craig A. ; et al. | 2012-04-05 |
| Phthalimide Derivative Metabotropic Glutamate R4 Ligands App 20110318266 - McCauley; John A. | 2011-12-29 |
| Macrocyclic quinoxaline compounds as HCV NS3 protease inhibitors Grant 8,080,654 - Harper , et al. December 20, 2 | 2011-12-20 |
| Sulfonamide Derivative Metabotropic Glutamate R4 Ligands App 20110243844 - McCauley; John A. | 2011-10-06 |
| Macrocyclic Quinoxaline Compounds As Hcv Ns3 Protease Inhibitors App 20110224134 - Harper; Steven ; et al. | 2011-09-15 |
| Macrocyclic quinoxaline compounds as HCV NS3 protease inhibitors Grant 7,973,040 - Harper , et al. July 5, 2 | 2011-07-05 |
| Hcv Ns3 Protease Inhibitors App 20110046161 - Liverton; Nigel J. ; et al. | 2011-02-24 |
| HCV NS3 Protease Inhibitors App 20110028494 - Holloway; M. Katharine ; et al. | 2011-02-03 |
| HCV NS3 protease inhibitors Grant 7,879,797 - Holloway , et al. February 1, 2 | 2011-02-01 |
| Therapeutic Compounds App 20110002884 - McCauley; John A. ; et al. | 2011-01-06 |
| HCV NS3 Protease Inhibitors App 20100286185 - Liverton; Nigel J ; et al. | 2010-11-11 |
| Macrocyclic Compounds As Antiviral Agents App 20100183551 - Harper; Steven ; et al. | 2010-07-22 |
| HCV NS3 Protease Inhibitors App 20100099695 - Liverton; Nigel J. ; et al. | 2010-04-22 |
| Hcv Ns3 Protease Inhibitors App 20100093779 - Liverton; Nigel J. ; et al. | 2010-04-15 |
| Macrocyclic Quinoxaline Compounds as HCV NS3 Protease Inhibitors App 20100029666 - Harper; Steven ; et al. | 2010-02-04 |
| 3-fluoro-piperidines as NMDA/NR2B antagonists Grant 7,592,360 - Liverton , et al. September 22, 2 | 2009-09-22 |
| Hcv Ns3 Protease Inhibitors App 20090124661 - HOLLOWAY; M. Katharine ; et al. | 2009-05-14 |
| HCV NS3 protease inhibitors App 20090075869 - Holloway; M. Katharine ; et al. | 2009-03-19 |
| HCV NS3 protease inhibitors Grant 7,470,664 - Holloway , et al. December 30, 2 | 2008-12-30 |
| 4-cycloakylaminopyrazolo pyrimidine NMDA/NR2B antagonists Grant 7,452,893 - Thompson , et al. November 18, 2 | 2008-11-18 |
| N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B Antagonists Grant 7,259,157 - Liverton , et al. August 21, 2 | 2007-08-21 |
| N-substituted nonaryl-heterocyclic nmda/nr2b antagonists App 20070149568 - Liverton; NigelJ ; et al. | 2007-06-28 |
| N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists Grant 7,217,716 - Claiborne , et al. May 15, 2 | 2007-05-15 |
| 4-Cycloakylaminopyrazolo pyrimidine nmda/nr2b antagonists App 20070037829 - Thompson; Wayne ; et al. | 2007-02-15 |
| HCV NS3 protease inhibitors App 20070027071 - Holloway; M. Katharine ; et al. | 2007-02-01 |
| N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists Grant 7,053,089 - Claiborne , et al. May 30, 2 | 2006-05-30 |
| 4-Cycloalkylaminopyrazolo pyrimidine NMDA/NR2B antagonists App 20050054658 - Thompson, Wayne ; et al. | 2005-03-10 |
| N-substituted nonaryl-heterocyclic nmda/nr2b antagonists App 20040209889 - Claiborne, Christopher F ; et al. | 2004-10-21 |
| N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B Antagonists App 20030119811 - Liverton, Nigel J. ; et al. | 2003-06-26 |
| N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists App 20020165241 - Claiborne, Christopher F. ; et al. | 2002-11-07 |
| 2-cyclohexyl imidazopyridine NMDA/NR2B antagonists App 20020055519 - Thompson, Wayne I. ; et al. | 2002-05-09 |
| 2-Cyclohexyl quinazoline NMDA/NR2B antagonists App 20020032207 - Thompson, Wayne ; et al. | 2002-03-14 |
| Iminopyrimidine NMDA NR2B receptor antagonists App 20020013329 - Claremon, David A. ; et al. | 2002-01-31 |
| 2-benzyl and 2-heteroaryl benzimidazole NMDA/NR2B antagonists Grant 6,316,474 - McCauley , et al. November 13, 2 | 2001-11-13 |
| Processes and intermediates for preparing macrocycles Grant 5,621,108 - Smith, III , et al. April 15, 1 | 1997-04-15 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 